Related Experiment Video
Updated: Aug 20, 2025
Establishment of the Dual Humanized TK-NOG Mouse Model for HIV-associated Liver Pathogenesis
Published on: September 11, 2019
Restoration of CD4+ T Cells during NAFLD without Modulation of the Hepatic Immunological Pattern Is Not Sufficient to
Madison Isbell1,2, Faridoddin Mirshahi3, Hussein F Aqbi1,4
1Department of Microbiology & Immunology, VCU School of Medicine, Richmond, VA 23298, USA.
Insights
Restoring CD4+ T cells in advanced nonalcoholic fatty liver disease (NAFLD) did not prevent liver cancer (HCC). Early intervention with SP16 peptide modulated inflammation, suggesting potential for future HCC prevention in NAFLD.
Area of Science:
- Hepatology
- Immunology
- Oncology
Background:
- Nonalcoholic fatty liver disease (NAFLD) progression is linked to inflammation and CD4+ T cell depletion.
- These factors are associated with the development of hepatocellular carcinoma (HCC).
Purpose of the Study:
- To investigate the effect of the LRP-1 agonistic peptide SP16 on NAFLD-associated immune changes.
- To determine if SP16 can prevent HCC progression in NAFLD models.
Main Methods:
- Administration of SP16 peptide during different stages of NAFLD progression.
- Analysis of CD4+ T cell populations and hepatic inflammatory profiles.
Main Results:
- SP16 administration in advanced NAFLD restored CD4+ T cells but did not alter the inflammatory pattern.
- Early SP16 administration modulated the inflammatory immune response in NAFLD.
- Restoring CD4+ T cells alone was insufficient to prevent HCC in advanced NAFLD.
Conclusions:
- Modulating the hepatic immune response early in NAFLD progression may be crucial for HCC prevention.
- Further research is needed to confirm if early SP16 intervention prevents HCC by regulating inflammation.
Abstract:
Predominant inflammatory immunological patterns as well as the depletion of CD4+ T cells during nonalcoholic fatty liver disease (NAFLD) are reported to be associated with the progression of hepatocellular carcinoma (HCC). Here, we report that an LRP-1 agonistic peptide, SP16, when administered during advanced NAFLD progression, restored the depleted CD4+ T cell population but did not significantly affect the inflammatory immunological pattern. This data suggests that restoration of CD4+ T cells without modulation of the hepatic immunological pattern is not sufficient to prevent HCC. However, SP16 administered early during NAFLD progression modulated the inflammatory profile. Future studies will determine if regulation of the inflammatory immune response by SP16 early in NAFLD progression will prevent HCC.
